Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages 782-783

  Ciccia, Francesco ^a   Giardina, Anna Rita ^a   Rizzo, Aroldo ^b   Guggino, Giuliana ^a   Cipriani, Paola ^c   Carubbi, Francesco ^c   Giacomelli, Roberto ^c   Triolo, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 22; RITUXIMAB;

ADULT; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNITY; LACRIMAL GLAND FUNCTION; LETTER; LYMPHANGIOGENESIS; LYMPHOCYTE DEPLETION; MALE; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; SYNOVIUM; T CELL LYMPHOMA; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKINS; MALE; MIDDLE AGED; SALIVARY GLANDS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84875961643     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202754     Document Type: Letter

References (9)

1. Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22 producing cells in the inflamed salivary glands of patients with Sjogren syndrome. Ann Rheum Dis 2012;71:295-301.
2. Bard JD, Gelebart P, Anand M, et al. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008;22:1595-603.
3. Gelebart P, Zak Z, Dien-Bard J, et al. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011;4:9-19.
4. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011;7:360-8.
5. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-16.
6. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237: 264-83.
7. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
8. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
9. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63:1507-16.